SAPHNELO™ (anifrolumab-fnia)

  • Home
  • SAPHNELO™ (anifrolumab-fnia)

SAPHNELO™ (anifrolumab-fnia) This information is intended for US Audiences Only. SAPHNELO is a trademark of the AstraZeneca group of companies.
©2021 AstraZeneca. All rights reserved.

US-53415 Last Updated 7/21 SAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines. It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. It is not known if SAPHNELO is safe and effective in patients under 18 y

ears of age. Please see full Prescribing Information (https://bit.ly/3xgURXR), including Patient Information (https://bit.ly/3zZjYjS).

Address


Website

Alerts

Be the first to know and let us send you an email when SAPHNELO™ (anifrolumab-fnia) posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Address
  • Alerts
  • Claim ownership or report listing

  • Want your practice to be the top-listed Clinic?

Share